Protein Sciences "avian flu" vaccine enters clinic: 1,000 doses delivered to NIH.
PROTEIN SCIENCES H5N1 INFLUENZA A VACCINE TO BEGIN CLINICAL TRIALS, the company announced Feb. 3 after delivering over 1,000 doses to the National Institutes of Health. The Hong Kong "avian flu" vaccine trial will enroll healthy adults, laboratory workers and health care personnel who are at risk of exposure to the virus and will have a primary endpoint of safety, National Institute of Allergy and Infectious Diseases Influenza Program Officer Dominick Iacuzio, PhD, told FDA's Vaccines and Related Biologics Advisory Committee Jan. 30.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth